P098 Role of serum lysol oxidase like 2 in Crohn's disease and modulation to biological treatment
M. J. Garcia Garcia*1, A. Garcia Blanco2, B. Castro Senosiain1, M. Pascual Mato1, C. Del Pozo Calzada1, J. Crespo Garcia1, M. Rivero Tirado1
1Marques De Valdecilla Universitary Hospital, Gastroenterology, Santander, Spain, 2Biotechnology and Biomedicine Institute of Cantabria (IBBTEC), Santander, Spain
Lysyl oxidase-like 2 (LOXL-2) expression at the level of the mucosa is elevated in diseases with fibrotic component, and also, has been involved in the biogenesis of connective tissue after the activation of the signalling pathway of TGF β-1. The aim of our study is the evaluation of serum levels of LOXL-2 in patients with Crohn's disease (CD) and assess the variability of the levels after the start of biological treatments.
We performed a cross-sectional study to determine the serum levels of LOXL-2 by enzyme-linked immunosorbent assay (ELISA) in patients with CD defined according to the European Crohn's and Colitis Organisation (ECCO). For this, 24 patients with Crohn's disease and 24 healthy controls were analysed matched by age and sex. The baseline characteristics of the patients were collected and biochemical parameters were also measured at baseline and 6 months after the start of the biological therapy. The patients were classified according to the response in responders and no responders.
LOXL 2 levels were higher in patients with CD (72.81 pg/ml (SD 24.65)) compared with healthy controls (31.40 pg/ml (SD 19.39)) in a significant way (
Serum levels of LOXL2 were elevated in patients with Crohn's disease and were significantly higher than the healthy control group. Patients who required previous surgery showed higher levels than those without surgery. More studies are needed to corroborate these results with a larger sample size to know the real involvement of LOXL2 in CD.